The possible benefit derived from icotinib, another EGFR-TKI, was evaluated in the EVIDENCE trial (NCT02448797, phase III), in which 322 stage II-IIIA EGFRm NSCLC pts were randomized to icotinib 125 mg × 3 die for 2 years or standard CT [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.